Hiraoka M - Search Results

1

ALC1/CHD1L, a chromatin-remodeling enzyme, is required for efficient base excision repair.

Tsuda M, Cho K, Ooka M, Shimizu N, Watanabe R, Yasui A, Nakazawa Y, Ogi T, Harada H, Agama K, Nakamura J, Asada R, Fujiike H, Sakuma T, Yamamoto T, Murai J, Hiraoka M, Koike K, Pommier Y, Takeda S, Hirota K. Tsuda M, et al. Among authors: hiraoka m. PLoS One. 2017 Nov 17;12(11):e0188320. doi: 10.1371/journal.pone.0188320. eCollection 2017. PLoS One. 2017. PMID: 29149203 Free PMC article.

2

Antitumor effect of TAT-oxygen-dependent degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells.

Harada H, Hiraoka M, Kizaka-Kondoh S. Harada H, et al. Among authors: hiraoka m. Cancer Res. 2002 Apr 1;62(7):2013-8. Cancer Res. 2002. PMID: 11929818

3

Tumor hypoxia: a target for selective cancer therapy.

Kizaka-Kondoh S, Inoue M, Harada H, Hiraoka M. Kizaka-Kondoh S, et al. Among authors: hiraoka m. Cancer Sci. 2003 Dec;94(12):1021-8. doi: 10.1111/j.1349-7006.2003.tb01395.x. Cancer Sci. 2003. PMID: 14662015 Free PMC article. Review.

4

Real-time imaging of hypoxia-inducible factor-1 activity in tumor xenografts.

Liu J, Qu R, Ogura M, Shibata T, Harada H, Hiraoka M. Liu J, et al. Among authors: hiraoka m. J Radiat Res. 2005 Mar;46(1):93-102. doi: 10.1269/jrr.46.93. J Radiat Res. 2005. PMID: 15802864 Free article.

5

Aminopeptidase N/CD13 targeting fluorescent probes: synthesis and application to tumor cell imaging.

Zhang Z, Harada H, Tanabe K, Hatta H, Hiraoka M, Nishimoto S. Zhang Z, et al. Among authors: hiraoka m. Peptides. 2005 Nov;26(11):2182-7. doi: 10.1016/j.peptides.2005.03.049. Peptides. 2005. PMID: 15885853

6

A tumor-specific gene therapy strategy targeting dysregulation of the VHL/HIF pathway in renal cell carcinomas.

Ogura M, Shibata T, Yi J, Liu J, Qu R, Harada H, Hiraoka M. Ogura M, et al. Among authors: hiraoka m. Cancer Sci. 2005 May;96(5):288-94. doi: 10.1111/j.1349-7006.2005.00044.x. Cancer Sci. 2005. PMID: 15904470 Free PMC article.

7

Optical imaging of tumor hypoxia and evaluation of efficacy of a hypoxia-targeting drug in living animals.

Harada H, Kizaka-Kondoh S, Hiraoka M. Harada H, et al. Among authors: hiraoka m. Mol Imaging. 2005 Jul-Sep;4(3):182-93. doi: 10.1162/15353500200505112. Mol Imaging. 2005. PMID: 16194450

8

Antitumor protein therapy; application of the protein transduction domain to the development of a protein drug for cancer treatment.

Harada H, Kizaka-Kondoh S, Hiraoka M. Harada H, et al. Among authors: hiraoka m. Breast Cancer. 2006;13(1):16-26. doi: 10.2325/jbcs.13.16. Breast Cancer. 2006. PMID: 16518058 Free article. Review.

9

Mechanism of hypoxia-specific cytotoxicity of procaspase-3 fused with a VHL-mediated protein destruction motif of HIF-1alpha containing Pro564.

Harada H, Kizaka-Kondoh S, Hiraoka M. Harada H, et al. Among authors: hiraoka m. FEBS Lett. 2006 Oct 16;580(24):5718-22. doi: 10.1016/j.febslet.2006.09.025. Epub 2006 Sep 22. FEBS Lett. 2006. PMID: 17010341 Free article.

10

Vertebrate POLQ and POLbeta cooperate in base excision repair of oxidative DNA damage.

Yoshimura M, Kohzaki M, Nakamura J, Asagoshi K, Sonoda E, Hou E, Prasad R, Wilson SH, Tano K, Yasui A, Lan L, Seki M, Wood RD, Arakawa H, Buerstedde JM, Hochegger H, Okada T, Hiraoka M, Takeda S. Yoshimura M, et al. Among authors: hiraoka m. Mol Cell. 2006 Oct 6;24(1):115-25. doi: 10.1016/j.molcel.2006.07.032. Mol Cell. 2006. PMID: 17018297 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,278 results

Search Page

Filters